Tumor genomics and response to chemotherapy in advanced non-small cell lung cancer with exon 20 insertion epidermal growth factor receptor mutations
Yue Wang, Jingwen Li, Yan Zhou, Shuhui Cao, Xuxinyi Ling, Yao Zhang, Wei Nie, Hua Zhong

Common mutations and the number of concomitant mutations ≤1 correlate with a biomarker that predicts benefit from chemotherapy and confers excellent prognosis for advanced patients with advanced EGFR ex20ins NSCLC. Patients with common mutations and with only one concomitant mutation had the greatest PFS and patients with uncommon mutations, and with over one concomitant mutation had the worst prognosis.

Ann Transl Med. 2020 Oct; 8(20): 1297.

Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer
Hong Tao, Liang Shi, Aoxue Zhou, Hongxia Li, Fei Gai, Zhan Huang, Nanying Che, Zhe Liu

This study illustrated the patterns of EML4-ALK fusion variants and gene profiles in patients with resected NSCLC. Advanced T stage and EML4-ALK variant 3 were associated with worse prognosis. The role of TP53 mutations in prognosis is worthy of further study.

Lung Cancer. 2020 Nov;149:154-161. 

Genetic profiling of primary and secondary tumors from patients with lung adenocarcinoma and bone metastases reveals targeted therapy options
Long Huang, Xiao-Liu Jiang, Hong-Bin Liang, Jian-Cheng Li, Li-Han Chin, Jian-Ping Wei, Rui-Ru Wang, Jing Cai, Qiang Xiong, Lien-Tu Wang, David S. Cram & An-Wen Liu

ARMS-PCR identified 14 EGFR positive, 3 EGFR negative and 1 ALK fusion positive patient. A therapy regimen incorporating TKIs Gefitinib and Crizotinib was offered to the EGFR and ALK fusion positive patients, respectively.

Mol Med. 2020 Sep 17;26(1):88. 

Comparison of Molecular, Clinicopathological, and Pedigree Differences Between Lynch-Like and Lynch Syndromes
Yun Xu, Zonghao Huang, Cong Li, Congcong Zhu, Yuqin Zhang, Tian'an Guo, Fangqi Liu, Ye Xu

In this study, we compared the molecular, clinical, and pathological characteristics, as well as pedigrees, between patients with Lynch-like syndrome (LLS) and confirmed Lynch syndrome (LS) to develop appropriate management strategies for patients with LLS and their affected family members.

Front Genet. 2020 Aug 19;11:991.

Afatinib in patients with advanced non-small cell lung cancer harboring HER2 mutations, previously treated with chemotherapy: A phase II trial
"Yun Fan, Jianhua Chen, Chengzhi Zhou, Huijuan Wang, Yongqian Shu, Jacky Zhang, Hairui Hua, Dennis Chin-Lun Huang, Caicun Zhou"

This study found no clinical benefit of afatinib for EGFR TKI-naïve patients with HER2m+ NSCLC.

"Lung Cancer Volume 147, September 2020, Pages 209-213"

Impact of ALK variants on brain metastasis and treatment response in advanced NSCLC patients with oncogenic ALK fusion
Meng Qiao, Chao Zhao, Qian Liu, Yan Wang, Jingyun Shi, Terry L Ng, Fei Zhou, Xuefei Li, Tao Jiang, Shuo Yang, Guanghui Gao, Anwen Xiong, Jiayu Li, Wei Li, Fengying Wu, Xiaoxia Chen, Chunxia Su, Shengxiang Ren, Caicun Zhou, Jun Zhang

Patients with ALK variant 1 and baseline BM had inferior TTF on first-line crizotinib treatment and presented with more aggressive radiological features. Patients with ALK non-variant 1 had better clinical outcome on first-line chemotherapy.

Transl Lung Cancer Res. 2020 Aug;9(4):1452-1463.

am8亚美下载